Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?

Breast Cancer Research and Treatment

Volumn 86, Issue 2, 2004, Pages 181-189

  Ogston, Keith N ^a   Miller, Iain D ^a   Schofield, Andrew C ^a   Spyrantis, Andreas ^a   Pavlidou, Eleni ^a   Sarkar, Tarun K ^b   Hutcheon, Andrew W ^b   Payne, Simon ^a   Heys, Steven D ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Breast cancer; Primary chemotheraphy

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CATHEPSIN D; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PREDNISOLONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 3342896685     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000032986.00879.d7     Document Type: Article

References (53)

1. Fisher B, Brown A, Mamounas E et al.: Effect of pre-operative chemotherapy on the outcome in women with operable breast cancer. J Clin Oncol 16: 2272-2685, 1998
2. Ragaz J, Baird R, Rebbeck P et al.: Pre-operative versus post-operative chemotherapy for stage I-II breast cancer: long term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 16: 142a, 1997 (Abstract)
3. Mauriac L, MacGrogan G, Avril A et al.: Neoadjuvant chemotherapy for breast cancers larger than 3 cms. A unicentre randomised trialwith a 124 month follow up. Ann Oncol 10: 47-52, 1999
4. Semiglazov VF, Topuzov EE, Bavli JL et al.: Primary chemotherapy and radiotherapy compared with primary chemotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591-595, 1994
5. Scholl SM, Fourquet A, Aselain B et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 30A: 645-652, 1994
6. Makris A, Powles TJ, Ashley SE et al.: A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemo-endocrine therapy in primary breast cancer. Ann Oncol 9: 1179-1194, 1998
7. Powles TJ, Hickish TF, Makris A et al.: A randomised trial of chemo-endocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 546-552, 1995
8. Miller AB, Hoogstraten B, Staquet MD et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
9. Brittenden J, Heys SD, Miller I et al.: Dietry supplementation with L-arginine in patients with breast cancer (>4 cms) receiving multimodality treatment: report of a feasibility study. Br J Cancer 69: 918-921, 1994
10. Chollet P, Charrier S, Brain E et al.: Clinical and pathological responses to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862-866, 1997
11. Kuerer HM, Newman LA, Smith TL et al.: Clinical course of breast cancer patients with complete pathological primary tumour and lymph node response to doxorubicin based primary chemotherapy. J Clin Oncol 17: 460-469, 1999
12. Bonnadonna G, Valagussa P, Brambilla C et al.: Primary chemotherapy in operable breast cancer. Eight year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998
13. Verril MW, Ashley SE, Walsh GA et al.: Pathological complete response in patients treated with neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat 50: 328, 1998
14. MacGrogan G, Mauriac L, Durand M: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb-B2, MIB-1, pS2, GST. Br J Cancer 74: 1458-1465, 1996
15. Chang J, Powles TJ, Allred DC: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999
16. Sjostrom J, Blomquist C, Heikkila P et al.: Predictive value of p53, mdm-2, p21 and MIB-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3010, 2000
17. Gonzalez-Vela MC, Garijo MF, Fernandez F et al.: MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors. Histol Histopathol 16: 399-406, 2001
18. Lowe SW, Ruley HE, Jacks T et al.: P53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
19. Levine A, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991
20. Bonnetti A, Zaninelli M, Leone R et al.: Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4: 2331-2336, 1998
21. Ravaioli A, Bagli L, Zucchini A et al.: Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif 31: 113-126, 1998
22. Bottini A, Beruti A, Bersiga A et al.: P53 but not Bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000
23. Clahsen PC, van de Velde CJ, Duval C et al.: p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node negative early breast cancer. J Clin Oncol 16: 470-479, 1998
24. Ferreira CG, Tolis C, Giaccone G: p53 and chemosensitivity. Ann Oncol 10: 1011-1021, 1999
25. Yang QF, Sakurai T, Yoshimura G: Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance anticancer drugs in breast carcinoma. Breast Cancer Res Treat 61: 211-216, 2000
26. Rayter Z: Steroid receptors in breast cancer. Br J Surg 78: 528-535, 1991
27. Kaufmann M: Review of known prognostic variables - recent results. Cancer Res 140: 77-87, 1996
28. Bundred BJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137-142, 2001
29. MacGrogan G, Mauriac L, Durand M et al.: Primary chemotherapy in breast cancer: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erb-B2, MIB-1, pS2 and GST pi. Br J Cancer 74: 1458-1465, 1996
30. Takamura Y, Kobayashi H, Taguchi T et al.: Prediction of chemotherapeutic response by collagen gel droplet embedded culture drug sensitivity test in human breast cancers. Int J Cancer 98: 450-455, 2002
31. Jarvinen TA, Holli K, Kuukasjarvi T: Predictive value of topoisomerase I alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267-2273, 1998
32. Jansen RL, Hupperets PS, Arends JW et al.: pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer. Anticancer Res 18: 577-582, 1998
33. Miyoshi Y, Ando A, Takamura Y et al.: Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97: 129-132, 2002
34. Egawa C, Motomura K, Miyoshi Y et al.: Increased expression of BRCA1 mRNA predicts favourable response to anthracyclin containing chemotherapy in breast cancers. Breast Cancer Res Treat 78: 45-50, 2003
35. Egawa C, Miyoshi Y, Takamura Y et al.: Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95: 255-259, 2001
36. Smith IC, Heys SD, Hutcheon AW et al.: Neo-adjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002
37. Ogston KN, Miller I, Payne S et al.: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12: 320-327, 2003
38. Ellis PA, Smith IE, Detre S et al.: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116, 1998
39. Bruce DM, Heys SD, Payne S, Miller ID, Eremin O: Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 22: 42-46, 1996
40. Faneyte IF, Schrama JG, Peterse IL, Remijnse PL, Rodenhuis S, van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406-412, 2003
41. Spyratos F, Ferro-Pous M, Trassard M et al.: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cut-off value. Cancer 94: 2151-2159, 2002
42. Fisher B, Brown A, Mamounas E et al.: Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997
43. Eltahir A, Heys SD, Hutcheon AW et al.: Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 175: 127-132, 1998
44. Sjostrom J: Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 41: 334-345, 2002
45. Stearns V, Singh B, Tsangaris T et al.: A prospective randomised pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9: 124-133, 2003
46. Frassoldati A, Adami F, Banzi C et al.: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44: 185-192, 1997
47. Makris A, Powles TJ, Dowsett M et al.: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600
48. Van Poznak C, Tan L, Panageas KS et al.: Asessment of molecular markers of clinical sensitivity to single agent taxane therapy for metastatic breast cancer. J Clin Oncol 20: 2319-2326, 2002
49. Sjostrom J, Colan J, von Boguslawski K et al.: C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38: 535-542, 2002
50. Hamilton A, Larsimont D, Paridaens R et al.: A study of the value of p53, Her2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 1: 233-240, 2000
51. Buchholz TA, Davis DW, McConkey DJ et al.: Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9: 33-41, 2003
52. Chang JC, Wooten EC, Tsmeizon et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003
53. Pusztai L, Ayers M, Simmans FW et al.: Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc ASCO 22: 1, 2003